Drug
CORT118335 clinical trials
Also written CORT118335 and Miricorilant.
- studies test it
- 15
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
15 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 1
Corcept Therapeutics (14) · The Scripps Research Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CORT118335 is read from its arms, and is right about nine times in ten.
Testing it · 15
- Evaluating the Pharmacokinetics and Safety of MiricorilantCompletedPhase 1Corcept TherapeuticsNCT07553663Written as Miricorilant
- Evaluation of Miricorilant on Liver Fat in Patients With MASLDCompletedPhase 1Corcept TherapeuticsNCT06947304Written as Miricorilant
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)CompletedPhase 2Corcept TherapeuticsNCT06108219Written as Miricorilant (Cohort A)
- Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult SubjectsCompletedPhase 1Corcept TherapeuticsNCT07240116Written as Miricorilant Treatment A
- Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantCompletedPhase 1Corcept TherapeuticsNCT05553470Written as Miricorilant
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsCompletedPhase 2Corcept TherapeuticsNCT03818256Written as Miricorilant
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)CompletedPhase 1Corcept TherapeuticsNCT05117489Written as Miricorilant 150 mg
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)CompletedPhase 2Corcept TherapeuticsNCT04524403Written as Miricorlilant
- Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of MiricorilantCompletedPhase 1Corcept TherapeuticsNCT05712265Written as Miricorilant
- Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus PlaceboCompletedPhase 2The Scripps Research InstituteNCT04466215Written as Miricorilant
- Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)TerminatedPhase 2Corcept TherapeuticsNCT03823703Written as Miricorilant
- Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy ParticipantsCompletedPhase 1Corcept TherapeuticsNCT04672499Written as Miricorilant 300 mg tablets
- The Effect of CORT118335 on Olanzapine-Induced Weight GainCompletedPhase 1Corcept TherapeuticsNCT03877562Written as CORT118335
- Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male ParticipantsCompletedPhase 1Corcept TherapeuticsNCT03878264Written as CORT118335 Oral
- First-in-human Study in Healthy SubjectsCompletedPhase 1Corcept TherapeuticsNCT03315338Written as CORT118335, 25 mg